Harvard Bioscience released a November 2026 corporate presentation for investors. The material provided is introductory: it describes the kinds of financial and operating measures the presentation may address, but contains no reported results, numerical targets or specific business updates.
Key details
- The presentation identifies revenue, gross margin, adjusted EBITDA and its margin, cash and debt, growth, new products and market position as subjects of its forward-looking discussion. These are listed as areas that may be covered, not as specific forecasts or commitments in the material provided.
- Harvard Bioscience says it uses non-GAAP measures alongside its GAAP results, including adjusted operating income, adjusted net income, adjusted EBITDA, adjusted earnings per share, foreign-exchange-adjusted revenue and net debt.
- The company says its non-GAAP calculations exclude items it considers outside underlying operations. Those items include stock-based compensation, acquisition-related intangible amortization, restructuring charges, other operating expenses, goodwill impairment, interest and certain tax effects.
- The presentation cautions that forward-looking statements depend on assumptions and are subject to risks that could cause actual performance to differ.
Plain-English implications
The announcement makes the current investor presentation available; the material provided does not establish a change in strategy, guidance, capital structure or management. Its discussion of adjusted measures is a reminder that those figures exclude costs and should be considered alongside, rather than instead of, GAAP results.